One of the goals of the Rally for Medical Research, held in conjunction with the American Association for Cancer Research (AACR) 2013 Annual Meeting, earlier this month was to bring awareness to and education about the impact of the cuts in federal funding for medical research. Dana-Farber’s Kenneth C. Anderson, MD participated in the Rally. He says in this video, … Read more
Harold J. Burstein, MD, PhD, a Dana-Farber breast cancer specialist, discusses some of the important studies presented at the 2011 CTRC-AACR San Antonio Breast Cancer Symposium. The five-day meeting includes more than 1,000 scientific presentations, seminars, and posters, with a focus on emerging treatments in hard-to-treat populations, patients with metastatic breast cancer, and breast cancer … Read more
If COVID-19 has taught us anything, it’s that with funding and regulatory support, the scientific community can move quickly and produce miracles. So when President Joe Biden announced his commitment on Feb. 2, to cut cancer deaths by 50 percent over the next 25 years, it produced a wave of guarded optimism. “This is great … Read more
As a multi-sport athlete growing up, Allison Rebello loved being part of a team. Today, living with metastatic breast cancer (MBC), she credits three teams for helping her stay active and optimistic in the face of an incurable but treatable disease. Rebello’s care team at Susan F. Smith Center for Women’s Cancers at Dana-Farber/Brigham and … Read more
As a federal probation officer, Ryan Fox brings empathy to her role working with prisoners and their families. Knowing there is often more to a case than meets the eye, she partners with lawyers, judges, and others in the court system to give inmates a fresh start and an opportunity to tell their stories. She’s … Read more
After seeing few updates for more than two decades, treatment options for ovarian cancer are beginning to expand rapidly. As doctors and scientists have learned more about the molecular forces at work in ovarian cancer, and about the immune system’s role in fighting the disease, several new therapies are being used, either as FDA-approved drugs … Read more
In gynecologic cancers, immunotherapy is being used in all stages of treatment, and researchers are trying to enhance the effects of different immunotherapy approaches.
By Eric Bender Multiple myeloma is a poster child for recent advances in treatment: In the past decade, the U.S. Food and Drug Administration (FDA) approved no fewer than nine treatments for the blood cancer, and several more drug approvals appear to be near. Not coincidentally, multiple myeloma is also a popular target that researchers … Read more
Despite the research, the promising new drugs, the many ongoing clinical trials, lung cancer remains a disease that affects too many people, too often. For patients and family members, the disease carries an added burden: a stigma that lung cancer and smoking go hand in hand, and that lung cancer patients brought this on themselves. … Read more
Each year, Dana-Farber patients join clinicians, staff, and the Boston Red Sox to share their stories of inspiration and their belief in the research advances at Dana-Farber during the WEEI/NESN Jimmy Fund Radio-Telethon at Fenway Park. This year, nearly 100 patients, including Rayquan Fregeau, who used art and resources from the Betty Ann Blum and … Read more
By James Bond “How long will I live?” I asked my oncologist in Ohio in 1992, when I was 44 and diagnosed with multiple myeloma. “Three years,” he answered. Instead, I enjoyed 10 more years of active living. Then my disease began to overtake me; my kidneys were failing, I was unable to eat solid … Read more
Diffuse large B-cell lymphoma (DLBCL) is the most common form of non-Hodgkin lymphoma, diagnosed in more than 18,000 people in the U.S. every year. It is a fast-growing lymphoma that can arise in the lymph nodes or, more rarely, in organs such as the spleen, liver, and others. As its name indicates, DLBCL involves the … Read more
Dana-Farber researchers have found that a transcription factor called SOX17 gives colon cancer a safe space to develop.
Its nickname “the executioner protein” might give one the idea that BAX has a sinister role in cell life. But its killing has more to do with sacrifice than malice. When a human cell is suffering from a lack of oxygen, a toxin, a genetic mutation, or other source of stress, it may kill itself … Read more
As a veteran scuba diver who has donned her wetsuit around the globe, Stephanie Lafontaine is never more at peace than when deep below the water’s surface. Even if she’s sharing the depths with sharks, she considers it her happy place. So when Lafontaine, 42, learned in April 2019 that she had inflammatory breast cancer … Read more
A frequent component of treatment for breast cancer is surgery to remove the cancer. While mastectomy was more common in decades past, experts at Dana-Farber want you to know that science and treatment have advanced. Improved screening, early diagnosis, and advances in medicine are enabling many more patients to have the option of breast-conserving surgery, … Read more
What is NUT carcinoma? NUT carcinoma, formerly known as NUT-midline carcinoma, is a rare but very aggressive cancer that can develop anywhere in the body but usually starts in the head, neck, and lungs. It’s a squamous cell cancer — meaning it begins in squamous cells, which line hollow organs such as the windpipe and … Read more
Patti Keenan was a senior in high school before learning that the mysterious disease she was treated for twice as a young girl in the 60s was, in fact, a rare form of cancer. Her parents, not wanting to frighten Patti at a time when pediatric cancer survival rates were much lower, kept their daughter’s … Read more
As science and clinical medicine advance, oncologists increasingly face the challenge of information overload. It can be hard for oncologists, especially those in community practices who cover many cancers, to keep up with the influx of new therapies, biomarkers, and clinical trial results. The go-to solution has been the systematic review. Researchers team up to … Read more
Like a mill crumbling into a river, solid tumors constantly shed bits of themselves — including their DNA — into the bloodstream. This free-floating genetic material, known as circulating tumor DNA, or ctDNA, contains a trove of information about the tumor. Advances in technology have made it possible to extract ctDNA from a blood sample, … Read more